Advertisement

AstraNu raises $3.5M for chip-scale optical coherence tomography imager

Nokia Bell Labs spin-out says it has developed a low-cost, swept-source system aimed at healthcare applications.

18 November 2026


AstraNu, a 2025 spin-out from Nokia’s Bell Labs research operation in New Jersey, says it has raised $3.5 million in seed funding in support of a novel approach to chip-scale optical coherence tomography (OCT) imaging.

Founded by chief scientist Michael Eggleston and VP of engineering Bibek Samanta - who both still hold positions at Bell Labs - AstraNu is aiming to use the cash to expand its photonics development team, validate the performance of its engine, and prepare for volume manufacturing.

In a release announcing the funding round, which was led by the deep-tech venture outfit Celesta Capital, company president Kevin Blalock stated: “This funding enables us to drive our strategy forward by building out our photonics development team and manufacturing readiness ahead of customer volume.

“Celesta's backing, together with the New Jersey Innovation Evergreen Fund’s (NJIEF's) support, gives us the runway to get our engine into partner testbeds and validate the performance we have achieved.”

Telecom know-how

According to AstraNu’s web site, the idea is to reduce both the size and cost of OCT equipment while maintaining the kind of sensitivity and imaging performance demanded by healthcare applications - initially in ophthalmology, where adoption of such a system outside of dedicated clinics and in low-resource environments in particular could be transformational.

“Built on decades of photonics innovation at Bell Labs, Astranu’s integrated OCT platform applies telecom industry know-how, materials, and components to an existing healthcare market and its biggest challenges,” states the firm. “We will reduce the cost and size of OCT by orders of magnitude.”

The approach is based on swept-source OCT (SS-OCT), where an incident laser is swept through a range of wavelengths to generate images similar in appearance to those from an ultrasound imager but with much higher resolution.

Advertisement

“SS-OCT can deliver faster, deeper imaging than legacy spectral-domain OCT (SD-OCT), but to date its cost and size have limited the reach of its applications,” explained AstraNu in its funding release. “Developed at Nokia Bell Labs, AstraNu's engine delivers SS-OCT imaging performance at SD-OCT price points – [with] a module more than 10x smaller and significantly lower in cost than conventional swept-source systems.”

The firm’s business model is to supply that imaging engine to established medical device, imaging, and optics companies who want to integrate high-performance OCT into their own products - with ophthalmology, the largest current market for the technology, the initial commercial focus.

SPIE BiOS presentation

Shortly before setting up AstraNu, the startup’s founders presented details of their novel approach in a talk at SPIE’s BiOS conference in San Francisco, part of the wider Photonics West event.

According to an abstract summarizing that presentation, although recent advances in optoelectronic integration have already resulted in a number of chip-scale OCT systems, none of them have proved capable of combining a high sensitivity and imaging rate with such compact module-level integration.

“In addition, no previous chip-scale OCT implementation has operated at 1060 nm - a key wavelength range for ophthalmic imaging,” the team wrote. “In this work, we utilize our heterogeneous integrated SS-OCT platform to demonstrate high-performance imaging at 1310 nm, and for the first time demonstrate high-sensitivity imaging at 1060 nm.”

They achieved that by using hybrid integration techniques to package the OCT engine module into a volume of less than a cubic centimeter. That package included a planar lightwave circuit photonic chip, integrated balanced photodiodes, a collimating ball lens, and a co-packaged electrothermally actuated MEMS mirror to deliver high-sensitivity imaging at a 100 kHz laser repetition rate.

“These results serve as a major step towards the creation of a low-cost and miniaturized OCT system for widespread application beyond in-clinic ophthalmology,” concluded the team at the time.

Advertisement
Latest Stories
Article Tags
Advertisement
Advertisement